Background: Torsemide is a new loop diuretic that has shown, in short-term
studies, to induce a longer and higher diuretic and natriuretic action than
frusemide. However, torsemide long-term effects and complications have not
been sufficiently investigated. The aim was to compare the efficacy and sa
fety of torsemide versus frusemide in cirrhotic patients with uncomplicated
ascites. Methods: Forty-six patients were randomized in two groups to rece
ive torsemide 20 mg/day (n = 22) or frusemide 40 mg/day (n = 24). Both drug
s were administered in association with spironolactone 200 mg/day. The init
ial doses of diuretics were increased every 3 days up to 60, 120 and 400 mg
/day, respectively, if the body weight loss was less than 300 g/day or natr
iuresis was below 50 mEq/day. Results: Torsemide induced a significantly gr
eater diuretic response than frusemide at 24 h and the maximum diuresis whi
le mean diuresis Was similar in bath groups. Natriuresis was also higher wi
th torsemide but the difference was not significant, The body weight loss,
the treatment period, the ascites resolution and complications were similar
in both groups. Diuretic doses were increased in two patients treated with
torsemide and in nine patients treated with frusemide (P < 0.05). Conclusi
ons: These results show that torsemide is as effective and safe as frusemid
e for long-term treatment of cirrhotic patients with ascites.